Abcam (OTCMKTS:ABCZF – Get Rating) is one of 406 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Abcam to related businesses based on the strength of its dividends, risk, analyst recommendations, institutional ownership, earnings, valuation and profitability.
Institutional and Insider Ownership
43.6% of Abcam shares are held by institutional investors. Comparatively, 27.9% of shares of all “Biotechnology” companies are held by institutional investors. 23.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Abcam and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Abcam | N/A | N/A | 117.51 |
| Abcam Competitors | $373.71 million | $53.84 million | 19.12 |
Analyst Ratings
This is a breakdown of recent ratings for Abcam and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abcam | 0 | 0 | 0 | 0 | N/A |
| Abcam Competitors | 830 | 1971 | 6189 | 80 | 2.61 |
As a group, “Biotechnology” companies have a potential upside of 125.03%. Given Abcam’s rivals higher possible upside, analysts clearly believe Abcam has less favorable growth aspects than its rivals.
Profitability
This table compares Abcam and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abcam | N/A | N/A | N/A |
| Abcam Competitors | -477.67% | -67.10% | -24.73% |
Dividends
Abcam pays an annual dividend of C$0.07 per share and has a dividend yield of 0.4%. Abcam pays out 42.5% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 2.7% and pay out 3,338.5% of their earnings in the form of a dividend.
Summary
Abcam beats its rivals on 6 of the 10 factors compared.
About Abcam
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
